| 证券代码：600521 | 证券简称：华海药业 | 公告编号：临 2025-078 号 | | --- | --- | --- | | 债券代码：110076 | 债券简称：华海转债 | | 浙江华海药业股份有限公司 3. 差异化分红送转方案： 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/9 | － | 2025/7/10 | 2025/7/10 | 差异化分红送转：是 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 5 月 23 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 (1)差异化分红方案 每股分配比例 A 股每 ...

Group 1 - The innovative drug concept index rose by 3.01%, ranking third among concept sectors, with 187 stocks increasing in value [1][2] - Leading stocks included Qianyan Bio with a 20% limit up, Guizhou Bailing, Saily Medical, and Anglikang also hitting the limit up, while Kexing Pharmaceutical, Yuekang Pharmaceutical, and Shutaishen showed significant gains of 15.62%, 15.55%, and 15.34% respectively [1][2] - The stocks with the largest declines were Wantai Bio, Yaoshi Technology, and Ruilian New Materials, which fell by 1.31%, 1.27%, and 1.00% respectively [1] Group 2 - The innovative drug sector saw a net inflow of 2.374 billion yuan, with 125 stocks receiving net inflows, and 7 stocks exceeding 100 million yuan in net inflows [2][3] - Saily Medical led the net inflow with 177 million yuan, followed by Yipin Hong with 168 million yuan, Guizhou Bailing with 158 million yuan, and Huahai Pharmaceutical with 135 million yuan [2][3] - The top three stocks by net inflow ratio were Taiankang, Saily Medical, and Guizhou Bailing, with ratios of 20.64%, 19.83%, and 17.80% respectively [3] Group 3 - The innovative drug concept's top performers included Qianyan Bio, which rose by 20.02%, and other notable gainers such as Shutaishen and Yuekang Pharmaceutical with increases of 15.34% and 15.55% respectively [4] - The trading volume and turnover rates for leading stocks were significant, with Saily Medical showing a turnover rate of 29.87% and a price increase of 10.00% [3][4] - The overall market sentiment in the innovative drug sector appears positive, with substantial capital inflows and strong performance from key players [2][3]

Core Viewpoint - The cell immunotherapy concept has seen a significant increase of 3.12%, ranking as the second highest in concept sector gains, with notable inflows of capital into 29 stocks within this sector [2][3]. Group 1: Market Performance - As of July 1, the cell immunotherapy concept experienced a 3.12% increase, with 45 stocks rising, including Yangpu Medical at a 20% limit up, and others like Saily Medical, Yuekang Pharmaceutical, Shutaishen, and Rongchang Bio showing gains of 15.55%, 15.34%, and 13.04% respectively [2][3]. - The leading decliners in this sector included *ST Biology, He’s Eye Hospital, and ST Zhongzhu, which fell by 1.36%, 0.63%, and 0.60% respectively [2]. Group 2: Capital Inflows - The cell immunotherapy sector attracted a net inflow of 472 million yuan, with 29 stocks receiving capital inflows, and 6 stocks seeing inflows exceeding 50 million yuan [3][4]. - Saily Medical led the net inflow with 177 million yuan, followed by Huahai Pharmaceutical, Betta Pharmaceutical, and Yangpu Medical with net inflows of 135 million yuan, 81.83 million yuan, and 75.87 million yuan respectively [3][4]. Group 3: Capital Flow Ratios - The top stocks by net inflow ratio included Yangpu Medical at 36.23%, Saily Medical at 19.83%, and Huahai Pharmaceutical at 14.87% [4]. - The detailed capital flow for key stocks showed Saily Medical with a 10% increase and a turnover rate of 29.87%, while Yangpu Medical had a 19.94% increase with a turnover rate of 9.99% [4][5].

Core Viewpoint - The concept of generic drug consistency evaluation has seen a rise of 2.73%, ranking fifth among concept sectors, with significant inflows of capital into various stocks within this sector [1][2]. Group 1: Market Performance - As of July 1, the generic drug consistency evaluation concept experienced a 2.73% increase, with 120 stocks rising, including top performers like Fengyuan Pharmaceutical, Guizhou Bailing, and Anglikang, which hit the daily limit [1]. - The leading gainers in this sector included Yuekang Pharmaceutical (up 15.55%), Yipinhong (up 14.72%), and Hongri Pharmaceutical (up 8.13%) [1][2]. - Conversely, the stocks with the largest declines were Yiming Pharmaceutical, Yongtai Technology, and *ST Suwu, which fell by 2.16%, 1.71%, and 0.79% respectively [1]. Group 2: Capital Inflows - The generic drug consistency evaluation sector attracted a net inflow of 829 million yuan, with 74 stocks receiving capital inflows, and 13 stocks seeing over 50 million yuan in net inflows [2]. - The stock with the highest net inflow was Yipinhong, which saw 168 million yuan, followed by Guizhou Bailing and Huahai Pharmaceutical with net inflows of 158 million yuan and 135 million yuan respectively [2][3]. - The top three stocks by net inflow ratio were Fengyuan Pharmaceutical (24.78%), Guizhou Bailing (17.80%), and Huahai Pharmaceutical (14.87%) [3]. Group 3: Stock Performance Metrics - Yipinhong had a daily increase of 14.72% with a turnover rate of 5.65% and a net capital flow of approximately 168 million yuan [3]. - Guizhou Bailing increased by 10.04% with a turnover rate of 13.11% and a net capital flow of about 158 million yuan [3]. - Huahai Pharmaceutical rose by 5.74% with a turnover rate of 3.26% and a net capital flow of around 135 million yuan [3].

Core Points - Zhejiang Huahai Pharmaceutical Co., Ltd. has received the drug registration certificate for Nimodipine Tablets from the National Medical Products Administration, indicating compliance with drug registration requirements [1][4] - Nimodipine Tablets are indicated for improving low motivation due to sequelae of cerebral infarction and are particularly effective in early treatment of vascular dementia [2] - The company has invested approximately RMB 8.99 million in the research and development of Nimodipine Tablets [3] Drug Information - Drug Name: Nimodipine Tablets - Dosage Forms: Tablets - Specifications: 5mg, 10mg - Registration Category: Class 3 Chemical Drug - Approval Numbers: National Drug Approval Code H20254671, H20254672 [1][2] Market Impact - The approval of Nimodipine Tablets enhances the company's product line and market competitiveness, contributing positively to its business development [4] - The domestic market sales for Nimodipine Tablets are projected to be approximately RMB 555 million in 2024 [2]

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 2025-077 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 注册分类：化学药品 3 类 申请人：浙江华海药业股份有限公司 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的尼麦角林片的《药品注册证书》，现将 相关情况公告如下： 一、药品的基本情况 药品名称：尼麦角林片 剂型：片剂 规格：5mg、10mg 申请事项：药品注册（境内生产） 四、风险提示 公司高度重视药品研发，严格控制药品研发、生产、销售环节的质量和安全。 但产品的生产和销售容易受国家政策、市场环境等不确定因素的影响，敬请广大投 资者谨慎决策，注意防范投资风险。 药品批准文号：国药准字 H20254671、国药准字 H20254672 审批结论：根 ...

Group 1 - The company's main credit rating remains "AA" with a stable outlook [1] - The tracking credit rating for the "Huahai Convertible Bond" is also maintained at "AA" [1] - The rating was conducted by Shanghai New Century Credit Rating Investment Service Co., Ltd. based on a comprehensive analysis of the company's industry and operational status [1] Group 2 - The previous credit rating results for the company and the convertible bond were both "AA" as of June 28, 2024 [1] - The announcement is made in accordance with the relevant regulations of the Securities Issuance Registration Management Measures and the Shanghai Stock Exchange Listing Rules [1] - The announcement was issued by the Board of Directors of Zhejiang Huahai Pharmaceutical Co., Ltd. on June 27, 2025 [2]

| | | 根据《上市公司证券发行注册管理办法》和《上海证券交易所股票上市规则》等 有关规定，浙江华海药业股份有限公司（以下简称"公司"）委托信用评级机构上海 新世纪资信评估投资服务有限公司（以下简称"新世纪评估"）对公司于 2020 年 11 月 2 日公开发行的可转换公司债券（转债简称"华海转债"）进行了跟踪评级。 公司前次主体信用评级结果为"AA"，"华海转债"前次评级结果为"AA "， 评级机构为新世纪评估，评级时间为 2024 年 6 月 28 日。 新世纪评估在对公司所属行业及经营状况等进行综合分析与评估的基础上，于 2025 年 6 月 26 日出具了《2020 年浙江华海药业股份有限公司公开发行可转换公司债 券定期跟踪评级报告》【新世纪跟踪（2025）100187】，维持公司"AA"的主体信用等 级，评级展望维持"稳定"，同时维持"华海转债"跟踪信用等级"AA"。 特此公告。 浙江华海药业股份有限公司 董 事 会 股票简称：华海药业 股票代码：600521 公告编号：临 2025-076 号 浙江华海药业股份有限公司 关于"华海转债"2025 年跟踪评级结果的公告 本公司董事会及全体董事保证本 ...

内部编号:2025060255 2020 年浙江华海药业股份有限公司 公开发行可转换公司债券 定期跟踪评级报告 项目负责人: 王婷亚 翁斯詰 子的女 wty@shxsj.com ch = $11 1 6-5 wsz@shxsj.com 项目组成员: 张明海 Press 16.1 评级总监: 联系电话:(021)63501349 联系地址:上海市黄浦区汉口路 398 号华盛大厦 14 层 公司网站：www.shxsj.com 上海新世纪资信评估投资服务有限公司 Shanghai Brilliance Credit Rating & Investors Service Co., Ltd. 11 | | 跟踪评级概要 | | --- | --- | | 编号:【新世纪跟踪(2025)100187】 | | | 评级对象: | 2020年浙江华海药业股份有限公司公 | | | 华海转债 | | | 主体/展望/债项/评级时间 | | 本次跟踪: | AA/稳定/AA/2025年6月26日 | | 前次跟踪: | AA/稳定/AA/2024 年 6 月 28 日 | | 首次评级: | AA/稳定/AA/2020年6月 ...

Market Performance - The cell immunotherapy sector declined by 1.41%, ranking among the top losers in the concept sector as of the market close on June 26 [1] - Notable declines were observed in companies such as Rongchang Biologics, Yuyuan Pharmaceutical, and Huahai Pharmaceutical, while ST Xiangxue, Shutai Shen, and Tailin Biologics saw gains of 4.19%, 1.71%, and 1.42% respectively [1] Capital Flow - The cell immunotherapy sector experienced a net outflow of 796 million yuan, with 43 stocks facing net outflows, and 5 stocks seeing outflows exceeding 50 million yuan [1] - Rongchang Biologics led the outflow with 110 million yuan, followed by Hengrui Medicine, Huahai Pharmaceutical, and Yuyuan Pharmaceutical with outflows of 104 million yuan, 75 million yuan, and 70 million yuan respectively [1] Top Gainers and Losers - The top gainers in the cell immunotherapy sector included ST Xiangxue, Shutai Shen, and Tailin Biologics, while the largest losers were Rongchang Biologics, Hengrui Medicine, and Huahai Pharmaceutical [1][3] - The trading volume for Rongchang Biologics was notably high, with a turnover rate of 14.96% and a significant drop of 18.36% in stock price [2][3]